AMRI signed collaboration agreement with Metrion Biosciences

| By | CDMO, Drug Development, R&D
0
109

AMRI, a global contract research, development and manufacturing organization working with the life sciences industry to improve patient outcomes and quality of life, and Metrion Biosciences Limited, the specialist ion channel CRO and drug discovery company, announced they have signed a new collaboration agreement.

The alliance will promote Metrion’s electrophysiology and ion channel screening expertise to global pharmaceutical and biotechnology clients.

As part of the agreement, AMRI will be able to offer its customers access to Metrion’s broad portfolio of assay tools and technologies for ion channel screening, cardiac safety profiling and neuroscience applications. Metrion’s customers will benefit in turn from ready access to AMRI’s suite of integrated drug discovery solutions, including expertise in medicinal chemistry, high content imaging, cell-based assays, high-throughput screening and screening by mass spectrometry.

Headquartered in Albany, New York (USA), AMRI, a global contract research and manufacturing organization , partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical Services, API Manufacturing and Drug Product.

Metrion Biosciences is a specialist ion-channel contract research organization and drug discovery business. Based in Cambridge (UK), the company provides customers with access to a range of high quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences’ specialist ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization.